Moleculin Biotech Stock Performance
| MBRX Stock | USD 4.34 0.12 2.84% |
The company secures a Beta (Market Risk) of 0.96, which conveys possible diversification benefits within a given portfolio. Moleculin Biotech returns are very sensitive to returns on the market. As the market goes up or down, Moleculin Biotech is expected to follow. At this point, Moleculin Biotech has a negative expected return of -1.2%. Please make sure to verify Moleculin Biotech's information ratio, skewness, as well as the relationship between the Skewness and day typical price , to decide if Moleculin Biotech performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Moleculin Biotech has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 23.6 M | |
| Total Cashflows From Investing Activities | -13 K |
Moleculin | Build AI portfolio with Moleculin Stock |
Moleculin Biotech Relative Risk vs. Return Landscape
If you would invest 1,061 in Moleculin Biotech on November 15, 2025 and sell it today you would lose (627.00) from holding Moleculin Biotech or give up 59.1% of portfolio value over 90 days. Moleculin Biotech is currently does not generate positive expected returns and assumes 6.9163% risk (volatility on return distribution) over the 90 days horizon. In different words, 62% of stocks are less volatile than Moleculin, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Moleculin Biotech Target Price Odds to finish over Current Price
The tendency of Moleculin Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 4.34 | 90 days | 4.34 | about 67.87 |
Based on a normal probability distribution, the odds of Moleculin Biotech to move above the current price in 90 days from now is about 67.87 (This Moleculin Biotech probability density function shows the probability of Moleculin Stock to fall within a particular range of prices over 90 days) .
Moleculin Biotech Price Density |
| Price |
Predictive Modules for Moleculin Biotech
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Moleculin Biotech. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Moleculin Biotech Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Moleculin Biotech is not an exception. The market had few large corrections towards the Moleculin Biotech's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Moleculin Biotech, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Moleculin Biotech within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -1.27 | |
β | Beta against Dow Jones | 0.96 | |
σ | Overall volatility | 2.09 | |
Ir | Information ratio | -0.18 |
Moleculin Biotech Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Moleculin Biotech for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Moleculin Biotech can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Moleculin Biotech generated a negative expected return over the last 90 days | |
| Moleculin Biotech has high historical volatility and very poor performance | |
| Net Loss for the year was (21.76 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Moleculin Biotech currently holds about 58 M in cash with (23.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.03. | |
| Moleculin Biotech has a frail financial position based on the latest SEC disclosures |
Moleculin Biotech Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Moleculin Stock often depends not only on the future outlook of the current and potential Moleculin Biotech's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Moleculin Biotech's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 137.7 K | |
| Cash And Short Term Investments | 4.3 M |
Moleculin Biotech Fundamentals Growth
Moleculin Stock prices reflect investors' perceptions of the future prospects and financial health of Moleculin Biotech, and Moleculin Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Moleculin Stock performance.
| Return On Equity | -5.04 | ||||
| Return On Asset | -0.67 | ||||
| Current Valuation | 6.5 M | ||||
| Shares Outstanding | 49.5 M | ||||
| Price To Earning | (3.81) X | ||||
| Price To Book | 476.20 X | ||||
| EBITDA | (26.52 M) | ||||
| Cash And Equivalents | 58 M | ||||
| Cash Per Share | 2.03 X | ||||
| Total Debt | 478 K | ||||
| Debt To Equity | 0.01 % | ||||
| Book Value Per Share | (0.24) X | ||||
| Cash Flow From Operations | (23.86 M) | ||||
| Earnings Per Share | (3.74) X | ||||
| Total Asset | 16.93 M | ||||
| Retained Earnings | (153.37 M) | ||||
| Current Asset | 28.09 K | ||||
| Current Liabilities | 772.79 K | ||||
About Moleculin Biotech Performance
Evaluating Moleculin Biotech's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Moleculin Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Moleculin Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.Things to note about Moleculin Biotech performance evaluation
Checking the ongoing alerts about Moleculin Biotech for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Moleculin Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Moleculin Biotech generated a negative expected return over the last 90 days | |
| Moleculin Biotech has high historical volatility and very poor performance | |
| Net Loss for the year was (21.76 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Moleculin Biotech currently holds about 58 M in cash with (23.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.03. | |
| Moleculin Biotech has a frail financial position based on the latest SEC disclosures |
- Analyzing Moleculin Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Moleculin Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Moleculin Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Moleculin Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Moleculin Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Moleculin Biotech's stock. These opinions can provide insight into Moleculin Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Moleculin Stock Analysis
When running Moleculin Biotech's price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.